REFERÈNCIES


Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15613-7.


Cullen BR

Daar ES, Moudgil T, Meyer RD, Ho DD.


de Jong MD, de Boer RJ, de Wolf F, Foudraine NA, Boucher CA, Goudsmit J, Lange JM.

de Santis C, Lopalco L, Robbioni P, Longhi R, Rappocciolo G, Siccardi AG, Beretta A.
Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells. AIDS Res Hum Retroviruses. 1994 Feb;10(2):157-62.

Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM.


Delassus S, Cheynier R, Wain-Hobson S.


Hanna GJ, D’Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
Mireia Arnedo Valero

Referències


Harrigan PR, Whaley M, Montaner JS.
Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.


Harrowe G, Cheng-Mayer C.


Haslett PA, Nixon DF, Shen Z, Larsson M, Cox WI, Manandhar R, Donahoe SM, Kaplan G.
Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.

A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy.

Havlir DV, Lange JM.
New antiretrovirals and new combinations.


A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998 Feb;42(2):269-76.


Kellam P, Larder BA. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol. 1995


Koot M, Vos AH, Keet RP, de Goede RE, Derksen MW, Terpstra FG, Coutinho RA, Miedema F, Tersmette M.
HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.

Korber BT, Maclinnes K, Smith RF, Myers G.
Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1.

Koup RA.
Virus escape from CTL recognition.


Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS.
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.


Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection.

Kure K, Llena JF, Lyman WD, Soeiro R, Weidenheim KM, Hirano A, Dickson DW.

Kuritzkes DR, Bell S, Bakhtiari M.


Lewin SR, Vesanen M, Kostrikis L, Hurley A, Duran M, Zhang L, Ho DD, Markowitz M.
Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy.


Lifson AR, Buchbinder SP, Sheppard HW, Mawle AC, Wilber JC, Stanley M, Hart CE, Hessol NA, Holmberg SD.
Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics.

Lifson AR, Hessol NA, Buchbinder SP, O'Malley PM, Barnhart L, Segal M, Katz MH, Holmberg SD.
Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection.

Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F.
HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.

Control of HIV despite the discontinuation of antiretroviral therapy.


Lori F, Malych A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC.
Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.


a. Meynard L, Miedema F. Programmed death of T cells in the course of HIV infection.


Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F.


Polis MA, Masur H. Predicting the progression to AIDS. Am J Med. 1990 Dec;89(6):701-5.


Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984; 224: 497-500.

Powderly WG, Sesion M, Conant M et al. The efficacy of viracept in pivotal phase I/III double-blind randomized controlled trials as monotherapy and in combination with D4T or AZT/3TC. 4th Conference on Retroviruses and Opportunistic Infections. Washington DC (USA) 1997


REFERÈNCIES


**Saag MS**.

**Sabino EC**, Delwart E, Lee TH, Mayer A, Mullins JI, Busch MP.


**Saksela K**, Stevens CE, Rubinstein P, Taylor PE, Baltimore D.

Shafer RW, Gonzales MJ, and Brun-Vezinet. Online comparison of HIV-1 drug resistance algorithms identifies rates and causes of discordant interpretation. Antiviral Ther 2001; 6(suppl 1):101


**Wain-Hobson S.**

**Wain-Hobson S.**

**Wain-Hobson S.**

**Wain-Hobson S.**


**Wildemann B**, Haas J, Ehrhart K et al. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1 infected patients both simultaneously in plasma but also between different body compartments such as blood and CSF. Neurology 1993; 43:2659-2663
Wolfs TF, Zwart G, Bakker M, Goudsmit J. 


Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. 

Wodarz D. 


Yagi MJ, Chu FN, Jiang JD, Wallace J, Mason P, Liu Y, Carafa J, Bekesi JG. 
Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection. Clin Immunol Immunopathol. 1992 May;63(2):126-34.

Yamaguchi Y, Gojobori T. 


207
Yusa K, Kavlick MF, Mitsuya H. HIV-1 acquires resistance to multiple classes of antiviral drugs through recombination. 4th Conference on Retroviruses and Opportunistic Infections. Whasington DC (USA) 1997


